Elanco Animal Health (ELAN) Cash & Equivalents (2017 - 2026)

Elanco Animal Health has disclosed Cash & Equivalents across 10 years of filings, most recently posting $530.0 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 1.67% year-over-year to $530.0 million; the TTM figure through Jun 2026 stood at $530.0 million (down 1.67% YoY), while the FY2025 annual figure was $545.0 million, up 16.45% from the prior year.
• Cash & Equivalents came in at $530.0 million for Q2 2026 at Elanco Animal Health, up from $428.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $545.0 million in Q4 2025 to a low of $318.0 million in Q1 2023.
• Average Cash & Equivalents over 5 years is $434.1 million, with a median of $444.0 million recorded in 2022.
• Year-over-year, Cash & Equivalents sank 45.92% in 2022 and soared 41.16% in 2025.
• Over 5 years, Cash & Equivalents stood at $345.0 million in 2022, then rose by 2.03% to $352.0 million in 2023, then soared by 32.95% to $468.0 million in 2024, then grew by 16.45% to $545.0 million in 2025, then slipped by 2.75% to $530.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $530.0 million in Q2 2026, $428.0 million in Q1 2026, and $545.0 million in Q4 2025.